Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer

J. R. Murren, S. Anderson, J. Fedele, G. Pizzorno, D. Belliveau, D. Zelterman, B. A. Burtness, I. Tocino, Stuart D Flynn, D. Beidler, Y. C. Cheng

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: Based on preclinical data that demonstrated synergy between alkylating agents and topoisomerase (topo) I poisons, we determined the maximum-tolerated dose (MTD) of topotecan, using a 5 day bolus schedule, that could be given in combination with a single, fixed dose of cyclophosphamide. Pharmacodynamics of this combination were explored by analyzing biochemical effects of treatment in peripheral-blood mononuclear cells (PBMCs). Patients and Methods: Patients with refractory cancer were treated with cyclophosphamide 600 mg/m2 on day 1, followed by topotecan given as a 30- minute infusion for 5 consecutive days. Cycles were repeated every 3 weeks. Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan. Plasma concentrations of topotecan were determined during the first treatment cycle by high-performance liquid chromatography. PBMCs were sampled at baseline and throughout the 5-day treatment period for analysis of topo I protein concentrations and to determine drug-induced DNA fragmentation. Results: Twenty-six patients were treated with topotecan at doses that ranged from 0.5 mg/m2/d to 1.2 mg/m2/d for a total of 74 cycles. Reversible neutropenia was dose-limiting, with mild to moderate suppression of the other blood-cell elements commonly occurring. Transfusions of RBCs and platelets were required in 24% and 7% of treatment cycles, respectively. The most prominent nonhematologic toxicities were fatigue and weight loss. Compared with previously published data in which topotecan was administered alone, cyclophosphamide did not appear to alter the pharmacokinetics of topotecan. Significant increases in topo I concentration were identified in PBMCs following the administration of cyclophosphamide on day 1 and there was a significant decrease in topo I during the 5-day course of treatment (P < .01, sign test). DNA fragmentation as a result of drug treatment was identified in 11 of 15 (73%) cycles analyzed. Conclusion: For previously treated patients, the recommended dose of topotecan in this schedule is 0.75 mg/m2/d without growth factor support and 1.0 mg/m2/d if it is administered with G-CSF. Biochemical changes in cells induced by exposure to camptothecins can be measured in viva and these effects may have important implications in the design of combination therapies and the optimal scheduling of this class of agents.

Original languageEnglish (US)
Pages (from-to)148-157
Number of pages10
JournalJournal of Clinical Oncology
Volume15
Issue number1
StatePublished - Jan 1997
Externally publishedYes

Fingerprint

Topotecan
Cyclophosphamide
Type I DNA Topoisomerase
Blood Cells
Neoplasms
Maximum Tolerated Dose
Granulocyte Colony-Stimulating Factor
DNA Fragmentation
Therapeutics
Appointments and Schedules
Camptothecin
Platelet Transfusion
Poisons
Alkylating Agents
Neutropenia
Pharmaceutical Preparations
Fatigue
Weight Loss
Intercellular Signaling Peptides and Proteins
Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Murren, J. R., Anderson, S., Fedele, J., Pizzorno, G., Belliveau, D., Zelterman, D., ... Cheng, Y. C. (1997). Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal of Clinical Oncology, 15(1), 148-157.

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. / Murren, J. R.; Anderson, S.; Fedele, J.; Pizzorno, G.; Belliveau, D.; Zelterman, D.; Burtness, B. A.; Tocino, I.; Flynn, Stuart D; Beidler, D.; Cheng, Y. C.

In: Journal of Clinical Oncology, Vol. 15, No. 1, 01.1997, p. 148-157.

Research output: Contribution to journalArticle

Murren, JR, Anderson, S, Fedele, J, Pizzorno, G, Belliveau, D, Zelterman, D, Burtness, BA, Tocino, I, Flynn, SD, Beidler, D & Cheng, YC 1997, 'Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer', Journal of Clinical Oncology, vol. 15, no. 1, pp. 148-157.
Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal of Clinical Oncology. 1997 Jan;15(1):148-157.
Murren, J. R. ; Anderson, S. ; Fedele, J. ; Pizzorno, G. ; Belliveau, D. ; Zelterman, D. ; Burtness, B. A. ; Tocino, I. ; Flynn, Stuart D ; Beidler, D. ; Cheng, Y. C. / Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 1. pp. 148-157.
@article{799521fc93ef4ff3b431dadb238fb898,
title = "Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer",
abstract = "Purpose: Based on preclinical data that demonstrated synergy between alkylating agents and topoisomerase (topo) I poisons, we determined the maximum-tolerated dose (MTD) of topotecan, using a 5 day bolus schedule, that could be given in combination with a single, fixed dose of cyclophosphamide. Pharmacodynamics of this combination were explored by analyzing biochemical effects of treatment in peripheral-blood mononuclear cells (PBMCs). Patients and Methods: Patients with refractory cancer were treated with cyclophosphamide 600 mg/m2 on day 1, followed by topotecan given as a 30- minute infusion for 5 consecutive days. Cycles were repeated every 3 weeks. Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan. Plasma concentrations of topotecan were determined during the first treatment cycle by high-performance liquid chromatography. PBMCs were sampled at baseline and throughout the 5-day treatment period for analysis of topo I protein concentrations and to determine drug-induced DNA fragmentation. Results: Twenty-six patients were treated with topotecan at doses that ranged from 0.5 mg/m2/d to 1.2 mg/m2/d for a total of 74 cycles. Reversible neutropenia was dose-limiting, with mild to moderate suppression of the other blood-cell elements commonly occurring. Transfusions of RBCs and platelets were required in 24{\%} and 7{\%} of treatment cycles, respectively. The most prominent nonhematologic toxicities were fatigue and weight loss. Compared with previously published data in which topotecan was administered alone, cyclophosphamide did not appear to alter the pharmacokinetics of topotecan. Significant increases in topo I concentration were identified in PBMCs following the administration of cyclophosphamide on day 1 and there was a significant decrease in topo I during the 5-day course of treatment (P < .01, sign test). DNA fragmentation as a result of drug treatment was identified in 11 of 15 (73{\%}) cycles analyzed. Conclusion: For previously treated patients, the recommended dose of topotecan in this schedule is 0.75 mg/m2/d without growth factor support and 1.0 mg/m2/d if it is administered with G-CSF. Biochemical changes in cells induced by exposure to camptothecins can be measured in viva and these effects may have important implications in the design of combination therapies and the optimal scheduling of this class of agents.",
author = "Murren, {J. R.} and S. Anderson and J. Fedele and G. Pizzorno and D. Belliveau and D. Zelterman and Burtness, {B. A.} and I. Tocino and Flynn, {Stuart D} and D. Beidler and Cheng, {Y. C.}",
year = "1997",
month = "1",
language = "English (US)",
volume = "15",
pages = "148--157",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer

AU - Murren, J. R.

AU - Anderson, S.

AU - Fedele, J.

AU - Pizzorno, G.

AU - Belliveau, D.

AU - Zelterman, D.

AU - Burtness, B. A.

AU - Tocino, I.

AU - Flynn, Stuart D

AU - Beidler, D.

AU - Cheng, Y. C.

PY - 1997/1

Y1 - 1997/1

N2 - Purpose: Based on preclinical data that demonstrated synergy between alkylating agents and topoisomerase (topo) I poisons, we determined the maximum-tolerated dose (MTD) of topotecan, using a 5 day bolus schedule, that could be given in combination with a single, fixed dose of cyclophosphamide. Pharmacodynamics of this combination were explored by analyzing biochemical effects of treatment in peripheral-blood mononuclear cells (PBMCs). Patients and Methods: Patients with refractory cancer were treated with cyclophosphamide 600 mg/m2 on day 1, followed by topotecan given as a 30- minute infusion for 5 consecutive days. Cycles were repeated every 3 weeks. Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan. Plasma concentrations of topotecan were determined during the first treatment cycle by high-performance liquid chromatography. PBMCs were sampled at baseline and throughout the 5-day treatment period for analysis of topo I protein concentrations and to determine drug-induced DNA fragmentation. Results: Twenty-six patients were treated with topotecan at doses that ranged from 0.5 mg/m2/d to 1.2 mg/m2/d for a total of 74 cycles. Reversible neutropenia was dose-limiting, with mild to moderate suppression of the other blood-cell elements commonly occurring. Transfusions of RBCs and platelets were required in 24% and 7% of treatment cycles, respectively. The most prominent nonhematologic toxicities were fatigue and weight loss. Compared with previously published data in which topotecan was administered alone, cyclophosphamide did not appear to alter the pharmacokinetics of topotecan. Significant increases in topo I concentration were identified in PBMCs following the administration of cyclophosphamide on day 1 and there was a significant decrease in topo I during the 5-day course of treatment (P < .01, sign test). DNA fragmentation as a result of drug treatment was identified in 11 of 15 (73%) cycles analyzed. Conclusion: For previously treated patients, the recommended dose of topotecan in this schedule is 0.75 mg/m2/d without growth factor support and 1.0 mg/m2/d if it is administered with G-CSF. Biochemical changes in cells induced by exposure to camptothecins can be measured in viva and these effects may have important implications in the design of combination therapies and the optimal scheduling of this class of agents.

AB - Purpose: Based on preclinical data that demonstrated synergy between alkylating agents and topoisomerase (topo) I poisons, we determined the maximum-tolerated dose (MTD) of topotecan, using a 5 day bolus schedule, that could be given in combination with a single, fixed dose of cyclophosphamide. Pharmacodynamics of this combination were explored by analyzing biochemical effects of treatment in peripheral-blood mononuclear cells (PBMCs). Patients and Methods: Patients with refractory cancer were treated with cyclophosphamide 600 mg/m2 on day 1, followed by topotecan given as a 30- minute infusion for 5 consecutive days. Cycles were repeated every 3 weeks. Once the MTD was defined, granulocyte colony-stimulating factor (G-CSF) was added to the regimen in an attempt to escalate further the dose of topotecan. Plasma concentrations of topotecan were determined during the first treatment cycle by high-performance liquid chromatography. PBMCs were sampled at baseline and throughout the 5-day treatment period for analysis of topo I protein concentrations and to determine drug-induced DNA fragmentation. Results: Twenty-six patients were treated with topotecan at doses that ranged from 0.5 mg/m2/d to 1.2 mg/m2/d for a total of 74 cycles. Reversible neutropenia was dose-limiting, with mild to moderate suppression of the other blood-cell elements commonly occurring. Transfusions of RBCs and platelets were required in 24% and 7% of treatment cycles, respectively. The most prominent nonhematologic toxicities were fatigue and weight loss. Compared with previously published data in which topotecan was administered alone, cyclophosphamide did not appear to alter the pharmacokinetics of topotecan. Significant increases in topo I concentration were identified in PBMCs following the administration of cyclophosphamide on day 1 and there was a significant decrease in topo I during the 5-day course of treatment (P < .01, sign test). DNA fragmentation as a result of drug treatment was identified in 11 of 15 (73%) cycles analyzed. Conclusion: For previously treated patients, the recommended dose of topotecan in this schedule is 0.75 mg/m2/d without growth factor support and 1.0 mg/m2/d if it is administered with G-CSF. Biochemical changes in cells induced by exposure to camptothecins can be measured in viva and these effects may have important implications in the design of combination therapies and the optimal scheduling of this class of agents.

UR - http://www.scopus.com/inward/record.url?scp=17144447367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144447367&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 148

EP - 157

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -